Journal Article
. 2017 Jun;47(2).
doi: 10.1002/jmri.25796.

Apparent diffusion coefficient in estrogen receptor-positive and lymph node-negative invasive breast cancers at 3.0T DW-MRI: A potential predictor for an oncotype Dx test recurrence score

Sunitha B Thakur 1 Manuela Durando 2 Soledad Milans 2 Gene Y Cho 2 Lucas Gennaro 2 Elizabeth J Sutton 2 Dilip Giri 3 Elizabeth A Morris 2 
  • PMID: 28640531
  •     29 References
  •     8 citations


Purpose: To measure the apparent diffusion coefficient (ADC) values in estrogen receptor-positive (ER+) and axillary lymph node-negative (LN-) invasive breast cancer and investigate the correlation of ADC with Oncotype Dx test recurrence scores (ODxRS).

Materials And Methods: This was a Health Insurance Portability and Accountability Act (HIPAA)-compliant single-site retrospective study. Patients underwent preoperative 3.0T MRI scans with additional diffusion-weighted imaging sequential scans (b = 0, 600 and b = 0, 1000 s/mm2 ) from January 2011 to 2013. The study population included 31 ER+/LN- invasive breast cancers, which underwent ODxRS genomic testing. ADC600 and ADC1000 parametric maps were generated, and ADC values were calculated from a user-drawn region of interest. ODxRS predicts 10-year recurrence risk in individual patients: low (RS <18), intermediate (RS: 18-30), or high (RS >30). All breast lesions, including subgroups of invasive ductal carcinoma (IDC) lesions and mass-only lesions were dichotomized by RS scores, low-risk versus intermediate/high-risk, and statistical analysis was performed using Mann-Whitney's test (statistical significance at P < 0.05) and receiver operating characteristic (ROC) curves. Multivariate analysis was also performed.

Results: Invasive breast cancers, when scored as low-risk by ODxRS, had significantly higher ADC values compared with intermediate/high-risk lesions for both ADC600 (P = 0.007) and ADC1000 (P = 0.008) mean values. This was true both when analyzing only mass-lesions (P = 0.03 and 0.01) or only IDCs (P = 0.001 and 0.009).

Conclusion: Preliminary findings suggest that lesion ADC values correlate with recurrence risk likelihood stratified using ODxRS. Hence, ADC is a potential surrogate biomarker for tumor aggressiveness.

Level Of Evidence: 3 Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2018;47:401-409.

Keywords: apparent diffusion coefficient; breast cancer; diffusion weighted MRI; dynamic contrast enhanced MRI; recurrence scores.

Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.
Sheridan Wilson, Caroline Speers, +4 authors, Caroline Lohrisch.
Clin Breast Cancer, 2015 Dec 26; 16(4). PMID: 26705158
Tumor heterogeneity: causes and consequences.
Andriy Marusyk, Kornelia Polyak.
Biochim Biophys Acta, 2009 Nov 26; 1805(1). PMID: 19931353    Free PMC article.
Highly Cited. Review.
Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.
Elizabeth J Sutton, Jung Hun Oh, +5 authors, Elizabeth A Morris.
J Magn Reson Imaging, 2015 Apr 09; 42(5). PMID: 25850931    Free PMC article.
Highly Cited.
Can Diffusion-Weighted Imaging and Related Apparent Diffusion Coefficient be a Prognostic Value in Women With Breast Cancer?
Paola Rabasco, Rocchina Caivano, +10 authors, Aldo Cammarota.
Cancer Invest, 2017 Jan 21; 35(2). PMID: 28107084
Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging.
Riham H Ei Khouli, Michael A Jacobs, +4 authors, David A Bluemke.
Radiology, 2010 Jun 25; 256(1). PMID: 20574085    Free PMC article.
Highly Cited.
Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness.
M Costantini, P Belli, +5 authors, L Bonomo.
Clin Radiol, 2010 Nov 13; 65(12). PMID: 21070905
Prediction of Low versus High Recurrence Scores in Estrogen Receptor-Positive, Lymph Node-Negative Invasive Breast Cancer on the Basis of Radiologic-Pathologic Features: Comparison with Oncotype DX Test Recurrence Scores.
Vandana Dialani, Shantanu Gaur, +5 authors, Priscilla J Slanetz.
Radiology, 2016 Mar 05; 280(2). PMID: 26937802
Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
Julianne R Biroschak, Gordon F Schwartz, +4 authors, Sun Yong Lee.
Breast J, 2013 Apr 26; 19(3). PMID: 23614365
Apparent Diffusion Coefficient in Invasive Ductal Breast Carcinoma: Correlation with Detailed Histologic Features and the Enhancement Ratio on Dynamic Contrast-Enhanced MR Images.
Roka Namoto Matsubayashi, Teruhiko Fujii, +2 authors, Seiya Momosaki.
J Oncol, 2010 Sep 28; 2010. PMID: 20871661    Free PMC article.
Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging.
Nathan S White, Carrie McDonald, +25 authors, Anders M Dale.
Cancer Res, 2014 Sep 04; 74(17). PMID: 25183788    Free PMC article.
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Correlations between apparent diffusion coefficient values of invasive ductal carcinoma and pathologic factors on diffusion-weighted MRI at 3.0 Tesla.
Sung Hee Park, Hye-Young Choi, Soo Yeon Hahn.
J Magn Reson Imaging, 2013 Dec 20; 41(1). PMID: 24353241
Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer.
S Y Choi, Y-W Chang, +3 authors, D Y Seo.
Br J Radiol, 2011 Dec 01; 85(1016). PMID: 22128125    Free PMC article.
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.
Farin Kamangar, Graça M Dores, William F Anderson.
J Clin Oncol, 2006 May 10; 24(14). PMID: 16682732
Highly Cited.
Apparent diffusion coefficient on 3.0 Tesla magnetic resonance imaging and prognostic factors in breast cancer.
C De Felice, V Cipolla, +4 authors, M L Meggiorini.
Eur J Gynaecol Oncol, 2014 Aug 15; 35(4). PMID: 25118482
Quantitative apparent diffusion coefficient measurement obtained by 3.0Tesla MRI as a potential noninvasive marker of tumor aggressiveness in breast cancer.
Manuela Durando, Lucas Gennaro, +7 authors, Sunitha B Thakur.
Eur J Radiol, 2016 Aug 10; 85(9). PMID: 27501902    Free PMC article.
Heterogeneity of breast cancer: etiology and clinical relevance.
V Almendro, G Fuster.
Clin Transl Oncol, 2011 Nov 16; 13(11). PMID: 22082639
Distinct effects of nuclear volume fraction and cell diameter on high b-value diffusion MRI contrast in tumors.
Nathan S White, Anders M Dale.
Magn Reson Med, 2013 Dec 21; 72(5). PMID: 24357182    Free PMC article.
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?
Monica Maria Yepes, Ada Pat Romilly, +5 authors, Stefan Glück.
Breast Cancer Res Treat, 2014 Sep 30; 148(1). PMID: 25262341
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma.
Su Kyung Jeh, Sung Hun Kim, +4 authors, Byung Joo Song.
J Magn Reson Imaging, 2010 Dec 25; 33(1). PMID: 21182127
MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays.
Hui Li, Yitan Zhu, +13 authors, Maryellen L Giger.
Radiology, 2016 Oct 19; 281(2). PMID: 27144536    Free PMC article.
Highly Cited.
Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.
Ahmed Bilal Ashraf, Dania Daye, +4 authors, Despina Kontos.
Radiology, 2014 Apr 08; 272(2). PMID: 24702725    Free PMC article.
Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors.
Ahmed Abdel Khalek Abdel Razek, Gada Gaballa, Adel Denewer, Nadia Nada.
NMR Biomed, 2010 Mar 17; 23(6). PMID: 20232453
Correlations between diffusion-weighted imaging and breast cancer biomarkers.
Laura Martincich, Veronica Deantoni, +9 authors, Filippo Montemurro.
Eur Radiol, 2012 Mar 14; 22(7). PMID: 22411304
Diffusion magnetic resonance imaging in breast cancer characterisation: correlations between the apparent diffusion coefficient and major prognostic factors.
Paolo Belli, Melania Costantini, +4 authors, Lorenzo Bonomo.
Radiol Med, 2014 Aug 07; 120(3). PMID: 25096888
Intravoxel incoherent motion diffusion-weighted MRI at 3.0 T differentiates malignant breast lesions from benign lesions and breast parenchyma.
Louisa Bokacheva, Jennifer B Kaplan, +6 authors, Sunitha B Thakur.
J Magn Reson Imaging, 2013 Nov 26; 40(4). PMID: 24273096    Free PMC article.
Correlations between apparent diffusion coefficient values and prognostic factors of breast cancer.
Takeshi Kamitani, Yoshio Matsuo, +10 authors, Hiroshi Honda.
Magn Reson Med Sci, 2013 Jul 17; 12(3). PMID: 23857151
Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers.
Nita Amornsiripanitch, Vicky T Nguyen, +4 authors, Savannah C Partridge.
J Magn Reson Imaging, 2017 Nov 28; 48(1). PMID: 29178616    Free PMC article.
Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk.
Jin You Kim, Jin Joo Kim, +8 authors, Robert Grimm.
Eur Radiol, 2019 Aug 07; 30(1). PMID: 31385051
Can apparent diffusion coefficient (ADC) distinguish breast cancer from benign breast findings? A meta-analysis based on 13 847 lesions.
Alexey Surov, Hans Jonas Meyer, Andreas Wienke.
BMC Cancer, 2019 Oct 17; 19(1). PMID: 31615463    Free PMC article.
Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results.
Doris Leithner, Joao V Horvat, +7 authors, Katja Pinker.
Breast Cancer Res, 2019 Sep 14; 21(1). PMID: 31514736    Free PMC article.
Differentiation of Breast Lesions and Distinguishing Their Histological Subtypes Using Diffusion-Weighted Imaging and ADC Values.
Jelena Maric, Jasmina Boban, +3 authors, Dragana Bogdanovic-Stojanovic.
Front Oncol, 2020 Apr 02; 10. PMID: 32232007    Free PMC article.
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
David C Newitt, Zheng Zhang, +18 authors, ACRIN Trial Team and I-SPY 2 TRIAL Investigators.
J Magn Reson Imaging, 2018 Oct 24; 49(6). PMID: 30350329    Free PMC article.
Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay.
Michael A Jacobs, Christopher B Umbricht, +5 authors, Antonio C Wolff.
Cancers (Basel), 2020 Oct 01; 12(10). PMID: 32992569    Free PMC article.
Diffusion-weighted imaging of the breast: current status as an imaging biomarker and future role.
Julia Camps-Herrero.
BJR Open, 2019 Mar 08; 1(1). PMID: 33178933    Free PMC article.